Skip to Content

S1803: Phase III Study of Daratumumab/rHuPH20 (NSC – 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Meyloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)


Clinical Trial Details »

Principal Investigator(s)
Vinod Parameswaran, MD

Clinical Trial Categories

  • Multiple Myeloma
Hematology Research Coordinators at 605-322-3090


  • Avera Cancer Institute at Sioux Falls
    1000 E. 23rd Street
    Sioux Falls, SD 57105
    Main: 605-322-3000
    Alternate: 800-657-4377

Moving Health Forward

Avera is a health ministry rooted in the Gospel. Our mission is to make a positive impact in the lives and health of persons and communities by providing quality services guided by Christian values.

© 2022 Avera Health, Sioux Falls, SD. All Rights Reserved.